Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$0.37 USD
-0.01 (-1.56%)
Updated Apr 19, 2024 03:57 PM ET
After-Market: $0.37 0.00 (-0.75%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GLMD 0.37 -0.01(-1.56%)
Will GLMD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GLMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLMD
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
GLMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Other News for GLMD
Hepion ends Phase 2 study for NASH drug due to cash restraints
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
Madrigal announces US launch of NASH/MASH drug Rezdiffra